Literature DB >> 19481315

Meningococcal protein antigens and vaccines.

Ian M Feavers1, Mariagrazia Pizza.   

Abstract

The development of a comprehensive vaccine against meningococcal disease has been challenging. Recent developments in molecular genetics have provided both explanations for these challenges and possible solutions. Since genome sequence data became available there has been a marked increase in number of protein antigens that have been suggested as prospective vaccine components. This review catalogues the proposed vaccine candidates and examines the evidence for their inclusion in potential protein vaccine formulations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19481315     DOI: 10.1016/j.vaccine.2009.05.001

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

1.  Refolding, purification and crystallization of the FrpB outer membrane iron transporter from Neisseria meningitidis.

Authors:  Muhammad Saleem; Stephen M Prince; Hema Patel; Hannah Chan; Ian M Feavers; Jeremy P Derrick
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-01-27

2.  Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university student cohort.

Authors:  Fadil A Bidmos; Keith R Neal; Neil J Oldfield; David P J Turner; Dlawer A A Ala'Aldeen; Christopher D Bayliss
Journal:  J Clin Microbiol       Date:  2010-12-01       Impact factor: 5.948

3.  Cellular Immune Responses in Humans Induced by Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines Given Separately and in Combination.

Authors:  Fredrik Oftung; Gro Ellen Korsvold; Audun Aase; Lisbeth M Næss
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

4.  Genetic characteristics of Neisseria meningitidis serogroup B strains carried by adolescents living in Milan, Italy: implications for vaccine efficacy.

Authors:  Susanna Esposito; Alberto Zampiero; Leonardo Terranova; Valentina Montinaro; Alessia Scala; Valentina Ansuini; Nicola Principi
Journal:  Hum Vaccin Immunother       Date:  2013-07-23       Impact factor: 3.452

5.  Label-free quantitative mass spectrometry for analysis of protein antigens in a meningococcal group B outer membrane vesicle vaccine.

Authors:  Lawrence W Dick; John T Mehl; John W Loughney; Anna Mach; Richard R Rustandi; Sha Ha; Lan Zhang; Craig T Przysiecki; Lance Dieter; Van M Hoang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 6.  MenB-FHbp Meningococcal Group B Vaccine (Trumenba®): A Review in Active Immunization in Individuals Aged ≥ 10 Years.

Authors:  Matt Shirley; Muhamed-Kheir Taha
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

7.  Slam is an outer membrane protein that is required for the surface display of lipidated virulence factors in Neisseria.

Authors:  Yogesh Hooda; Christine Chieh-Lin Lai; Andrew Judd; Carolyn M Buckwalter; Hyejin Esther Shin; Scott D Gray-Owen; Trevor F Moraes
Journal:  Nat Microbiol       Date:  2016-02-29       Impact factor: 17.745

Review 8.  Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease.

Authors:  Darryl J Hill; Natalie J Griffiths; Elena Borodina; Mumtaz Virji
Journal:  Clin Sci (Lond)       Date:  2010-02-09       Impact factor: 6.124

9.  Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival.

Authors:  Hebert Echenique-Rivera; Alessandro Muzzi; Elena Del Tordello; Kate L Seib; Patrice Francois; Rino Rappuoli; Mariagrazia Pizza; Davide Serruto
Journal:  PLoS Pathog       Date:  2011-05-05       Impact factor: 6.823

10.  Use of a molecular decoy to segregate transport from antigenicity in the FrpB iron transporter from Neisseria meningitidis.

Authors:  Muhammad Saleem; Stephen M Prince; Stephen E J Rigby; Muhammad Imran; Hema Patel; Hannah Chan; Holly Sanders; Martin C J Maiden; Ian M Feavers; Jeremy P Derrick
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.